David is Vice President of Clinical Pharmacology, Integrated Drug Development at, Certara. He provides strategic and integrated drug development expertise predominantly in Global Health, applying his clinical pharmacology and drug-development experience to malaria, neglected tropical disease, COVID-19, and other product investment and development teams. Over the past 30+ years, David has applied clinical pharmacology thinking and model-based drug development in government and pharmaceutical industry positions.
David has held positions at Parke-Davis Pharmaceutics, Pfizer Global Research and Development, Ovation Pharmaceuticals and Lundbeck LLC. In these positions, he has served in areas of clinical pharmacology, as an investigator in a Phase 1 clinical research unit, in experimental and translational medicine, and as senior medical director in multiple therapeutic areas. He has been an integral team member for multiple investigational new drug applications, new drug applications, and supplemental new drug applications for adult and pediatric indications.
David earned his MD and his PhD (Pharmacology) in 1983 from Indiana University School of Medicine. He completed his residency in Internal Medicine and was subsequently certified by the American Board of Internal Medicine. LTC Wesche completed his Fellowship in Clinical Pharmacology in a program sponsored jointly by the FDA and Walter Reed Army Institute of Research (WRAIR) at the Uniformed Services University of Health Sciences. While on active duty, he conducted research from bench to bedside in products for tropical diseases. Prior to this time, he served as medical superintendent and faculty member in Papua New Guinea.